TP53INP1和RAI2在三阴性乳腺癌中的表达及与患者预后的关系

doi:10.3969/j.issn.1671-7171.2023.10.017

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1181 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the expression levels of TP53INP1 and RAI2 in triple-negative breast cancer (TNBC) tissues and their relationships with the clinical and pathological characteristics and prognosis of patients. 【Methods】The protein expression levels of TP53INP1 and RAI2 in 168 TNBC patients were detected and analyzed in relation to the patients' clinical and pathological characteristics and prognosis. 【Results】The positive rates of TP53INP1 and RAI2 in TNBC cancer tissues were 23.21% (39/168) and 32.74% (55/168) respectively, significantly lower than the 53.57% (90/168) and 58.93% (99/168) in adjacent non-tumor tissues (P<0.05). The expression level of TP53INP1 was correlated with lymph node metastasis, histological grade, and TNM staging (P<0.05), while the expression level of RAI2 was correlated with lymph node metastasis and histological grade (P<0.05). Univariate analysis showed that lymphatic metastasis, TNM stage, TP53INP1 expression, and RAI2 expression were risk factors affecting overall survival and disease-free survival rates. The 5-year disease-free survival rate and overall survival rate of groups without lymph node metastasis, TNM stages Ⅰ-Ⅱ,high TP53INP1 expression, and high RAI2 expression were significantly higher than their corresponding groups, with statistically significant differences (P<0.05). Cox hazard regression model analysis showed that the expressions of TP53INP1, RAI2, and lymph node metastasis were independent prognostic factors affecting disease-free survival. 【Conclusion】The expression levels of TP53INP1 and RAI2 are closely related to the occurrence, progression, and poor prognosis of TNBC. High expression of TP53INP1 and RAI2 may indicate a good prognosis.

Key words： Breast Neoplasms/PA Receptor, ErbB-2 Estrogens Progesterone Prognosis

Received: 30 December 2022

PACS:

R737.9

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	PANG Zongxin
	SUN Xuan
	LIANG Qingna
	et al

Cite this article:

PANG Zongxin,SUN Xuan,LIANG Qingna, et al. Expression of TP53INP1 and RAI2 in Triple-Negative Breast Cancer and their Relationship with Patient Prognosis[J]. JOURNAL OF CLINICAL RESEARCH, 2023, 40(10): 1500-1503.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2023.10.017 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2023/V40/I10/1500

[1] POPEDA M,STOKOWY T,BEDNARZ-KNOLL N,et al.NF-kappa B Signaling-Related signatures are connected with the mesenchymal phenotype of circulating tumor cells in non-metastatic breast cancer[J].Cancers(Basel),2019, 1(12):1961.
[2] WANG Q, GAO J, DI W, et al. Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA overexpressed mouse tumor models[J].Cancer Immunol Immunother,2020, 69(9):1781-1799.
[3] AZIM HA J R,ROTHE F,AURA C M,et al.Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy:A sub-study from the NeoALTTO phase Ⅲ trial[J].Breast,2013,22(6):1060-1065.
[4] 中国女医师协会临床肿瘤学专业委员会. 中国进展期乳腺癌共识指南(CABC 2015)[J].癌症进展, 2015, 13(3):223-245.
[5] LIAO D,LI T,YE C,et al.miR-221 inhibits autophagy and targets TP53INP1 in colorectal cancer cells[J].Exp Ther Med,2018,15(2):1712-1717.
[6] NISHIMOTO M,NISHIKAWA S,KONDO N,et al.Prognostic impact of TP53INP1 gene expression in estrogen receptor α-positive breast cancer patients[J].Jpn J Clin Oncol,2019,49(6):567-575.
[7] FILIPOWICZ W,BHATTACHARYYA SN,SONENBERG N. Mechanisms of post-transcriptional regulation by microRNAs:are the answers in sight[J].Nat Rev Genet,2008,9(2):102-114.
[8] MAYER I A,ABRAMSON V G,FORMISANO L,et al. A Phase Ib study of alpelisib(BYL719) ,a PI3Kα-specific lnhibitor,with letrozole in ER⁺ /HER2-metastatic breast cancer[J].Clin Cancer Res,2017,23(1):26.
[9] SALAZAR LG,LU H,REICHOW JL,et al. Topical imiquimod plus nab-paclitaxel for breast cancer cutaneous metastases:A phase 2 clinical trial[J].JAMA Oncology,2017,3(7):969-973.
[10] GIOVANNELLIP P, DONATO M, AURICCHIO F, et al. Androgens induce invasiveness of triple negative breast cancer cells through AR/Src/PI3-K complex assembly[J].Sci Rep,2019, 9(1):4490.
[11] KIM S B, DENT R, IM S A, et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer(LOTUS):a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial[J].Lancet Oncol,2017, 18(10):1360-1372.
[12] LI C,WANG Q,SHEN S,et al.HIF-1α/VEGF signaling-mediated epithelial - mesenchymal transition and angiogenesis is critically involved in anti - metastasis effect of luteolin in melanoma cells[J].Phytother Res,2019,33(3):798-807.